Hypha Labs (FUNI) 10-Q 14 Aug 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jun. 30, 2017	Aug. 12, 2017
Document And Entity Information
Entity Registrant Name	DigiPath,Inc.
Entity Central Index Key	1,502,966
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		34,123,784
Trading Symbol	DIGP
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Current assets:
Cash	$ 113,963	$ 135,390
Accounts receivable, net	164,220	98,441
Prepaid expenses	72,650	24,246
Deposits	25,647	39,850
Total current assets	376,480	297,927
Fixed assets, net	1,089,720	1,139,748
Available-for-sale securities	6,640	9,200
Total Assets	1,472,840	1,446,875
Current liabilities:
Accounts payable	154,427	157,666
Accrued expenses	20,294	54,247
Total current liabilities	174,721	211,913
Total Liabilities	174,721	211,913
Stockholders’ Equity:
Series A convertible preferred stock, $0.001 par value, 10,000,000 shares authorized; 2,147,942 and 3,520,442 shares issued and outstanding at June 30, 2017 and September 30, 2016, respectively	2,148	3,520
Common stock, $0.001 par value, 90,000,000 shares authorized;32,040,450 and 22,491,041 shares issued and outstanding at June 30, 2017 and September 30, 2016, respectively	32,040	22,491
Additional paid-in capital	12,497,159	11,681,282
Accumulated other comprehensive loss	(43,360)	(40,800)
Accumulated (deficit)	(11,189,868)	(10,431,531)
Total Digipath, Inc. Stockholders' Equity	1,298,119	1,234,962
Noncontrolling interest
Total Stockholders’ Equity	1,298,119	1,234,962
Total Liabilities and Stockholders’ Equity	$ 1,472,840	$ 1,446,875

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Sep. 30, 2016
Statement of Financial Position [Abstract]
Series A Convertible Preferred stock, par value	$ 0.001	$ 0.001
Series A Convertible Preferred stock, shares authorized	10,000,000	10,000,000
Series A Convertible Preferred stock, shares issued	2,147,942	3,520,442
Series A Convertible Preferred stock, shares outstanding	2,147,942	3,520,442
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	32,040,450	22,491,041
Common stock, shares outstanding	32,040,450	22,491,041

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenues	$ 389,315	$ 264,178	$ 1,296,115	$ 507,430
Cost of sales	215,729	102,724	640,871	258,083
Gross profit	173,586	161,454	655,244	249,347
Operating expenses:
General and administrative	300,924	302,383	907,994	910,076
Professional fees	279,843	1,004,225	745,437	1,414,913
Bad debts expense	6,896	(30,646)	30,650	272,375
Total operating expenses	587,663	1,275,962	1,684,081	2,597,364
Operating loss	(414,077)	(1,114,508)	(1,028,837)	(2,348,017)
Other income (expense):
Other income	3,000	16,000	263,000	46,000
Interest income	2,500	2,500	7,500	7,500
Gain on early extinguishment of debt				12,133
Equity in losses of unconsolidated entity				(992,682)
Total other income (expense)	5,500	18,500	270,500	(927,049)
Net loss from continuing operations	(408,577)	(1,096,008)	(758,337)	(3,275,066)
Less: Net loss attributable to the noncontrolling interest
Net loss	$ (408,577)	$ (1,096,008)	$ (758,337)	$ (3,275,066)
Weighted average number of common shares outstanding - basic and fully diluted	31,542,189	20,342,817	27,849,386	17,225,893
Net loss per share - basic and fully diluted	$ (0.01)	$ (0.05)	$ (0.03)	$ (0.19)
Net loss attributable to Digipath, Inc.	$ (408,577)	$ (1,096,008)	$ (758,337)	$ (3,275,066)
Available-for-sale investments:
Change in net unrealized income (loss) (net of tax effect)	(9,080)	5,760	(2,560)	(360)
Comprehensive loss	$ (417,657)	$ (1,090,248)	$ (760,897)	$ (3,275,426)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Net loss	$ (758,337)	$ (3,275,066)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debts expense	30,650	272,375
Depreciation and amortization expense	186,922	183,392
Stock issued for services, related parties	79,024	35,000
Stock issued for services	145,270	53,720
Options and warrants granted for services, related parties	269,928	744,364
Options and warrants granted for services	29,832	274,127
Gain on early extinguishment of debt		(12,133)
Equity in losses of unconsolidated entity		992,682
Decrease (increase) in assets:
Accounts receivable	(96,429)	(106,283)
Prepaid expenses	(48,404)	(11,056)
Deposits	14,203	(675)
Increase (decrease) in liabilities:
Accounts payable	(3,239)	76,862
Accrued expenses	(33,953)	(21,671)
Deferred revenues		(4,167)
Net cash used in operating activities	(184,533)	(798,529)
Cash flows from investing activities
Cash disposed in divestiture of unconsolidated entity		(57,876)
Purchase of fixed assets	(136,894)	(11,192)
Net cash used in investing activities	(136,894)	(69,068)
Cash flows from financing activities
Proceeds from sale of common stock	300,000	460,000
Net cash provided by financing activities	300,000	460,000
Net decrease in cash	(21,427)	(407,597)
Cash - beginning	135,390	481,095
Cash - ending	113,963	73,498
Supplemental disclosures:
Interest paid
Income taxes paid
Non-cash investing and financing activities:
Net change in unrealized gain (loss) on available-for-sale securities	(2,560)	(360)
Value of preferred stock converted to common stock	$ 1,372,500	$ 730,000

Organization, Basis of Presenta

Organization, Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Organization, Basis of Presentation and Significant Accounting Policies	Note 1 – Organization, Basis of Presentation and Significant Accounting Policies Organization Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) supports the cannabis industry’s best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Our business units are described below. ● Digipath Labs, Inc ● The National Marijuana News Corp Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2016: State of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Entity formed for prospective purposes, but has not incurred any income or expenses to date. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Equity Method Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Consolidated Balance Sheets and Statements of Operations; however, the Company’s share of the earnings or losses of the Investee company is reflected in the caption “Equity in losses of unconsolidated entity” in the Consolidated Statements of Operations. The Company’s carrying value in an equity method Investee company is reflected in the caption “Investment in Digipath Corp.” in the Company’s Consolidated Balance Sheets. As of June 30, 2017, our share of losses from the investee company exceeded our basis, therefore the investment is not currently presented on the balance sheet. U.S. GAAP considers a change in reporting entity to include “changing specific subsidiaries that make up the group of entities for which consolidated financial statements are presented.” Circumstances may arise where a parent’s controlling financial interest (e.g., generally an ownership interest in excess of 50 percent of the outstanding voting stock) is reduced to a noncontrolling investment that still enables it to exercise significant influence over the operating and financial policies of the investee. A change that results from changed facts and circumstances (such as a partial sale of a subsidiary), where there was only one acceptable method of accounting prior to the change in circumstances (consolidation) and only one acceptable method of accounting after the change (equity method accounting), is not a change in reporting entity and is not be accounted for retrospectively. Accordingly, a change from a controlling interest to a noncontrolling investment accounted for under the equity method is accounted for prospectively from the date of change in control. When the Company’s carrying value in an equity method Investee company is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the Investee company or has committed additional funding. When the Investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized. Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short term nature of the instruments. In addition, the Company had debt instruments that required fair value measurement on a recurring basis. Revenue Recognition The Company recognizes revenue in accordance with ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery of product has met the criteria established in the arrangement or services rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured. This occurs when the products or services are completed in accordance with the contracts we have with clients. In connection with our products and services arrangements, when we are paid in advance, these amounts are classified as deferred revenue and amortized over the term of the agreement. With respect to our cannabis lab testing revenues, we sell our services on a determinable fixed fee per test, or panel of tests basis, and offer a discounted price for customers that agree to enter into exclusive, long term contracts. We typically require payment within thirty days of the delivery of results. Revenues are recognized upon the substantial completion of the tests when collectability is reasonably assured, which is usually upon delivery of results to the customer. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers Revenue from Contracts with Customers In October 2016, the FASB issued ASU No. 2016-17, Consolidation (Topic 810): Interests Held through Related Parties that are under Common Control In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	9 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying condensed consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of ($11,189,868), and as of June 30, 2017, the Company’s cash on hand may not be sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new customers to increase revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. Management believes these factors will contribute toward achieving profitability. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 3 – Related Party Transactions Stock Based Compensation for Services On March 1, 2017, we issued 25,000 shares of common stock to our CFO as a bonus for services rendered. The aggregate fair value of the common stock was $6,623 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On February 22, 2017, we issued 100,000 shares of common stock to Dr. Alfredo Axtmayer in connection with his appointment to our Board of Directors. The aggregate fair value of the common stock was $34,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On January 1, 2016, we issued 500,000 shares of common stock to an entity owned by our CEO as compensation for board services rendered during the 2016 calendar year. The aggregate fair value of the common stock was $70,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed in ratably over the requisite service period, resulting in $17,500 of stock based compensation expense during the nine months ended June 30, 2017. On June 21, 2016, we granted options to purchase 4,750,000 shares of common stock as compensation for services to our CEO. The options are exercisable over a ten year period at an exercise price of $0.20 per share, and 50% vest immediately, with 25% vesting each year thereafter. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 230% and a call option value of $0.1986, was $943,193. The options are being expensed over the vesting period, resulting in $176,850 of stock based compensation expense during the nine months ended June 30, 2017. On June 21, 2016, we granted options to purchase 2,500,000 shares of common stock as compensation for services to our President and COO. The options are exercisable over a ten year period at an exercise price of $0.20 per share, and 50% vest immediately, with 25% vesting each year thereafter. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 230% and a call option value of $0.1986, was $496,417. The options are being expensed over the vesting period, resulting in $93,078 of stock based compensation expense during the nine months ended June 30, 2017.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 4 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2017 and September 30, 2016, respectively: Fair Value Measurements at June 30, 2017 Level 1 Level 2 Level 3 Assets Cash $ 113,963 $ - $ - Available-for-sale securities 6,640 - - Total assets 120,603 - - Liabilities Total liabilities - - - $ 120,603 $ - $ - Fair Value Measurements at September 30, 2016 Level 1 Level 2 Level 3 Assets Cash $ 135,390 $ - $ - Available-for-sale securities 9,200 - - Total assets 144,590 - - Liabilities Total liabilities - - - $ 144,590 $ - $ - The fair value of our intellectual properties are deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the nine months ended June 30, 2017 or the year ended September 30, 2016.

Accounts Receivable

Accounts Receivable	9 Months Ended
	Jun. 30, 2017
Receivables [Abstract]
Accounts Receivable	Note 5 – Accounts Receivable Accounts receivable was $164,220 and $98,441 at June 30, 2017 and September 30, 2016, respectively, net of allowance for doubtful accounts of $23,150 and $-0- at June 30, 2017 and September 30, 2016, respectively.

Fixed Assets

Fixed Assets	9 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 6 – Fixed Assets Fixed assets consist of the following at June 30, 2017 and September 30, 2016: June 30, 2017 September 30, 2016 Software $ 121,617 $ 121,617 Office equipment 36,080 36,080 Furniture and fixtures 10,344 2,357 Lab equipment 938,449 811,623 Leasehold improvements 489,147 487,066 1,595,637 1,458,743 Less: accumulated depreciation (505,917 ) (318,995 ) Total $ 1,089,720 $ 1,139,748 On October 1, 2015, we disposed of fixed assets with a net book value of $3,122 pursuant to the deconsolidation of Digipath Corp. The fixed assets consisted of furniture and fixtures with a historical cost basis of $48,779 and software with a historical cost basis of $10,019, and accumulated depreciation of $48,779 and $6,897, respectively. No gain or loss was recognized on the disposals. Depreciation and amortization expense totaled $186,922 and $183,392 for the nine months ended June 30, 2017 and 2016, respectively.

Available-for-Sale Securities

Available-for-Sale Securities	9 Months Ended
	Jun. 30, 2017
Schedule of Investments [Abstract]
Available-for-Sale Securities	Note 7 – Available-for-Sale Securities Available-for-sale securities consist of the following at June 30, 2017 and September 30, 2016: For the Nine Months Ended June 30, 2017 Gains in Losses in Accumulated Accumulated Other Other Estimated Amortized Comprehensive Comprehensive Fair Cost Loss Loss Value Common stock $ 50,000 - $ (43,360 ) $ 6,640 Total available-for-sale securities $ 50,000 - $ (43,360 ) $ 6,640 For the Year Ended September 30, 2016 Gains in Losses in Accumulated Accumulated Other Other Estimated Amortized Comprehensive Comprehensive Fair Cost Loss Loss Value Common stock $ 50,000 - $ (40,800 ) $ 9,200 Total available-for-sale securities $ 50,000 - $ (40,800 ) $ 9,200 Common stock consisted of 400,000 shares of common stock of Blue Line Protection Group, Inc., a Nevada corporation, acquired in March of 2015 for $50,000.

Changes in Stockholders' Equity

Changes in Stockholders' Equity	9 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Changes in Stockholders' Equity	Note 8 - Changes in Stockholders’ Equity Convertible Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, of which 6,000,000 have been designated as Series A Convertible Preferred Stock (“Series A Preferred”). The Board of Directors is authorized to determine any number of series into which shares of preferred stock may be divided and to determine the rights, preferences, privileges and restrictions granted to any series of the preferred stock. As of June 30, 2017, there were 2,147,942 shares of Series A Preferred issued and outstanding. Shares of Series A Preferred are convertible into common stock at a fixed conversion rate of $0.20 per share. The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 2,147,942 shares of Series A Preferred outstanding at June 30, 2017 are convertible into 10,739,710 shares of the common stock of the Company. No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Preferred Stock Conversions During the nine months ended June 30, 2017, a total of 1,372,500 Series A Preferred shares were converted into 6,862,500 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Common stock consists of $0.001 par value, 90,000,000 shares authorized, of which 32,040,450 shares were issued and outstanding as of June 30, 2017. Common Stock Sales On June 21, 2017, the Company sold 333,334 units, consisting of 333,334 shares of its common stock and 166,667 warrants, exercisable at $0.26 per share over a thirty six month period, in exchange for total proceeds of $50,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On February 21, 2017, the Company sold 1,428,575 units, consisting of 1,428,575 shares of its common stock and 714,285 warrants, exercisable at $0.26 per share over a thirty six month period, in exchange for total proceeds of $250,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. The warrants were assigned to two individuals by the purchaser at the time of the sale. Common Stock Issued for Services On May 2, 2017, the Company issued 100,000 shares of common stock to Dr. John Abroon in connection with his appointment to our newly created Advisory Board. The aggregate fair value of the common stock was $20,900 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On May 2, 2017, the Company issued 140,000 shares of common stock to a consultant in consideration of services rendered from April 1, 2017 through May 31, 2017. The aggregate fair value of the common stock was $29,260 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On March 1, 2017, the Company issued 25,000 shares of common stock to its CFO as a bonus for services rendered. The aggregate fair value of the common stock was $6,623 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On March 1, 2017, the Company issued 50,000 shares of common stock to its Chief Scientist as a bonus for services rendered. The aggregate fair value of the common stock was $13,245 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On February 23, 2017, the Company issued 100,000 shares of common stock to a consultant for services to be rendered over a six month period. The aggregate fair value of the common stock was $29,000 based on the closing price of the Company’s common stock on the date of grant, and is being expensed over the requisite service period. On February 22, 2017, the Company issued 100,000 shares of common stock to Dr. Alfredo Axtmayer in connection with his appointment to our Board of Directors. The aggregate fair value of the common stock was $34,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On February 22, 2017, the Company issued 40,000 shares of common stock to a consultant for services rendered. The aggregate fair value of the common stock was $13,600 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On February 7, 2017, a total of 370,000 shares of common stock were issued to six consultants that were engaged to assist the Company with acquisition activities over a six month period. The aggregate fair value of the common stock was $82,251 based on the closing price of the Company’s common stock on the date of grant, and is being expensed over the six month requisite service period. On January 1, 2016, an affiliate of Mr. Bianco, a director of the Company, became entitled to receive 500,000 shares of common stock for consulting services to be performed during 2016, subject to a ratable “claw back” provision the event of an early termination of the consulting agreement. The total fair value of the common stock was $70,000 based on the closing price of the Company’s common stock on the date of grant, and is being expensed over the twelve month requisite service period, resulting in $17,500 of stock based compensation during the period. A total of $224,293 of stock-based compensation expense was recognized from the amortization of common stock issued for services over the requisite service period during the nine months ended June 30, 2017. Amortization of Stock Options A total of $299,760 of stock-based compensation expense was recognized from the amortization of options over their vesting period during the nine months ended June 30, 2017.

Common Stock Options

Common Stock Options	9 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock Options	Note 9 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012 and previously amended on May 20, 2014. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 shares of common stock pursuant to the grant of options or other awards, including stock grants, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the 2012 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. A total of 9,290,000 options were outstanding as of June 30, 2017. No options were granted or exercised during the nine months ended June 30, 2017. On January 1, 2017, options to purchase 1,530 shares of common stock at $3.30 per share expired.

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Common Stock Warrants	Note 10 – Common Stock Warrants A total of 5,074,088 warrants were outstanding as of June 30, 2017. No warrants were exercised or expired during the nine months ended June 30, 2017. Warrants to purchase a total of 166,667 shares of common stock at $0.26 per share over a 36 month period were issued on June 21, 2017 pursuant to a unit offering for the sale of 333,334 shares of common stock in exchange for proceeds of $50,000, and warrants to purchase a total of 714,285 shares of common stock at $0.26 per share over a 36 month period were issued on February 21, 2017 pursuant to a unit offering for the sale of 1,428,575 shares of common stock in exchange for proceeds of $250,000.

Other Income

Other Income	9 Months Ended
	Jun. 30, 2017
Other Income and Expenses [Abstract]
Other Income	Note 11 – Other Income Other income consists of rental income of $3,000 and $30,000 for the nine months ended June 30, 2017 and 2016, respectively, for office and storage space subleased, along with $250,000 received from GB Sciences, Inc. during the nine months ended June 30, 2017 pursuant to the settlement of a $300,000 license agreement with GB Sciences, Inc. In addition, we recognized $10,000 and $16,000 of other income for the nine months ended June 30, 2017 and 2016, respectively, related to restitution payments received from a former employee.

Income Tax

Income Tax	9 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Tax	Note 12 - Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the nine months ended June 30, 2017 and the year ended September 30, 2016, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At June 30, 2017, the Company had approximately $7,041,000 of federal net operating losses. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at June 30, 2017 and September 30, 2016, respectively. In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 13 – Subsequent Events Preferred Stock Conversions On August 10, 2017, a shareholder converted 150,000 shares of Series A Preferred into 750,000 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Sales On August 5, 2017, the Company sold 1,000,000 units, consisting of 1,000,000 shares of its common stock and 500,000 warrants, exercisable at $0.26 per share over a thirty six month period, in exchange for total proceeds of $150,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On July 28, 2017, the Company sold 333,334 units, consisting of 333,334 shares of its common stock and 166,667 warrants, exercisable at $0.26 per share over a thirty six month period, in exchange for total proceeds of $50,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

Organization, Basis of Presen19

Organization, Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Organization	Organization Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) supports the cannabis industry’s best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Our business units are described below. ● Digipath Labs, Inc ● The National Marijuana News Corp
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2016: State of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Entity formed for prospective purposes, but has not incurred any income or expenses to date. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Equity Method	Equity Method Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Consolidated Balance Sheets and Statements of Operations; however, the Company’s share of the earnings or losses of the Investee company is reflected in the caption “Equity in losses of unconsolidated entity” in the Consolidated Statements of Operations. The Company’s carrying value in an equity method Investee company is reflected in the caption “Investment in Digipath Corp.” in the Company’s Consolidated Balance Sheets. As of June 30, 2017, our share of losses from the investee company exceeded our basis, therefore the investment is not currently presented on the balance sheet. U.S. GAAP considers a change in reporting entity to include “changing specific subsidiaries that make up the group of entities for which consolidated financial statements are presented.” Circumstances may arise where a parent’s controlling financial interest (e.g., generally an ownership interest in excess of 50 percent of the outstanding voting stock) is reduced to a noncontrolling investment that still enables it to exercise significant influence over the operating and financial policies of the investee. A change that results from changed facts and circumstances (such as a partial sale of a subsidiary), where there was only one acceptable method of accounting prior to the change in circumstances (consolidation) and only one acceptable method of accounting after the change (equity method accounting), is not a change in reporting entity and is not be accounted for retrospectively. Accordingly, a change from a controlling interest to a noncontrolling investment accounted for under the equity method is accounted for prospectively from the date of change in control. When the Company’s carrying value in an equity method Investee company is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the Investee company or has committed additional funding. When the Investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.
Segment Reporting	Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short term nature of the instruments. In addition, the Company had debt instruments that required fair value measurement on a recurring basis.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery of product has met the criteria established in the arrangement or services rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured. This occurs when the products or services are completed in accordance with the contracts we have with clients. In connection with our products and services arrangements, when we are paid in advance, these amounts are classified as deferred revenue and amortized over the term of the agreement. With respect to our cannabis lab testing revenues, we sell our services on a determinable fixed fee per test, or panel of tests basis, and offer a discounted price for customers that agree to enter into exclusive, long term contracts. We typically require payment within thirty days of the delivery of results. Revenues are recognized upon the substantial completion of the tests when collectability is reasonably assured, which is usually upon delivery of results to the customer.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers Revenue from Contracts with Customers In October 2016, the FASB issued ASU No. 2016-17, Consolidation (Topic 810): Interests Held through Related Parties that are under Common Control In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Organization, Basis of Presen20

Organization, Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2016: State of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Entity formed for prospective purposes, but has not incurred any income or expenses to date.

Fair Value of Financial Instr21

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2017 and September 30, 2016, respectively: Fair Value Measurements at June 30, 2017 Level 1 Level 2 Level 3 Assets Cash $ 113,963 $ - $ - Available-for-sale securities 6,640 - - Total assets 120,603 - - Liabilities Total liabilities - - - $ 120,603 $ - $ - Fair Value Measurements at September 30, 2016 Level 1 Level 2 Level 3 Assets Cash $ 135,390 $ - $ - Available-for-sale securities 9,200 - - Total assets 144,590 - - Liabilities Total liabilities - - - $ 144,590 $ - $ -

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at June 30, 2017 and September 30, 2016: June 30, 2017 September 30, 2016 Software $ 121,617 $ 121,617 Office equipment 36,080 36,080 Furniture and fixtures 10,344 2,357 Lab equipment 938,449 811,623 Leasehold improvements 489,147 487,066 1,595,637 1,458,743 Less: accumulated depreciation (505,917 ) (318,995 ) Total $ 1,089,720 $ 1,139,748

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	9 Months Ended
	Jun. 30, 2017
Schedule of Investments [Abstract]
Schedule of Available-for-Sale Securities	Available-for-sale securities consist of the following at June 30, 2017 and September 30, 2016: For the Nine Months Ended June 30, 2017 Gains in Losses in Accumulated Accumulated Other Other Estimated Amortized Comprehensive Comprehensive Fair Cost Loss Loss Value Common stock $ 50,000 - $ (43,360 ) $ 6,640 Total available-for-sale securities $ 50,000 - $ (43,360 ) $ 6,640 For the Year Ended September 30, 2016 Gains in Losses in Accumulated Accumulated Other Other Estimated Amortized Comprehensive Comprehensive Fair Cost Loss Loss Value Common stock $ 50,000 - $ (40,800 ) $ 9,200 Total available-for-sale securities $ 50,000 - $ (40,800 ) $ 9,200

Organization, Basis of Presen24

Organization, Basis of Presentation and Significant Accounting Policies (Details Narrative)	9 Months Ended
	Jun. 30, 2017Segments
Number of reportable segment	1
Minimum [Member]
Percentage of equity method interest	20.00%
Maximum [Member]
Percentage of equity method interest	50.00%

Organization, Basis of Presen25

Organization, Basis of Presentation and Significant Accounting Policies - Schedule of Entities Under Common Control and Ownership (Details) - Entities Under Common Control and Ownership [Member]	9 Months Ended
	Jun. 30, 2017
Name of Entity	Digipath, Inc.	[1],[2]
State of Incorporation	Nevada	[2]
Relationship	Parent	[2]
Name of Entity	Digipath Labs, Inc.	[1]
State of Incorporation	Nevada
Relationship	Subsidiary
Name of Entity	TNM News, Inc.	[1]
State of Incorporation	Nevada
Relationship	Subsidiary
Name of Entity	GroSciences, Inc.	[1],[3]
State of Incorporation	Colorado	[3]
Relationship	Subsidiary	[3]
[1]	All entities are in the form of a corporation.
[2]	Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company.
[3]	Entity formed for prospective purposes, but has not incurred any income or expenses to date.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (11,189,868)	$ (10,431,531)

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 02, 2017	Feb. 22, 2017	Jan. 02, 2017	Jun. 21, 2016	Jan. 02, 2016	Jun. 30, 2017	Jun. 30, 2016	Feb. 21, 2017
Stock based compensation expense						$ 145,270	$ 53,720
Number of warrants to purchase of common stock shares			1,530
Common stock exercise price								$ 0.26
Chief Executive Officer [Member]
Common stock exercise price				$ 0.20
Call option value				$ 0.1986
CFO [Member]
Number of common stock shares issued for services	25,000
Stock option value	$ 6,623
Dr. Alfredo Axtmayer [Member]
Number of common stock shares issued for services		100,000
Stock option value		$ 34,000
Chief Executive Officer [Member]
Number of common stock shares issued for services					500,000
Stock option value				$ 943,193	$ 70,000
Stock based compensation expense						$ 17,500
Number of warrants to purchase of common stock shares				4,750,000
Options exercisable description				The options are exercisable over a ten year period
Percentage of options vested immediately				50.00%
Percentage of options vested thereafter				25.00%
Fair value measurements, volatility rate				230.00%
Chief Executive Officer [Member] | Joseph J. Bianco [Member]
Stock based compensation expense						176,850
President and COO [Member]
Stock option value				$ 496,417
Stock based compensation expense						$ 93,078
Number of warrants to purchase of common stock shares				2,500,000
Options exercisable description				The options are exercisable over a ten year period
Common stock exercise price				$ 0.20
Percentage of options vested immediately				50.00%
Percentage of options vested thereafter				25.00%
Fair value measurements, volatility rate				230.00%
Call option value				$ 0.1986

Fair Value of Financial Instr28

Fair Value of Financial Instruments - Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Level 1 [Member]
Cash	$ 113,963	$ 135,390
Available-for-sale securities	6,640	9,200
Assets	120,603	144,590
Total liabilities
Total	120,603	144,590
Level 2 [Member]
Cash
Available-for-sale securities
Assets
Total liabilities
Total
Level 3 [Member]
Cash
Available-for-sale securities
Assets
Total liabilities
Total

Accounts Receivable (Details Na

Accounts Receivable (Details Narrative) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Receivables [Abstract]
Accounts receivable	$ 164,220	$ 98,441
Allowance for doubtful accounts	$ 23,150	$ 0

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Oct. 02, 2016
Fixed assets book value			$ 3,122
Gain or loss recognized on disposals
Depreciation and amortization expense	$ 186,922	$ 183,392
Furniture and Fixtures [Member]
Fixed assets historical cost basis			48,779
Fixed assets accumulated depreciation and amortization			48,779
Software [Member]
Fixed assets historical cost basis			10,019
Fixed assets accumulated depreciation and amortization			$ 6,897

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Software	$ 121,617	$ 121,617
Office equipment	36,080	36,080
Furniture and fixtures	10,344	2,357
Lab equipment	938,449	811,623
Leasehold improvements	489,147	487,066
Fixed Assets, Gross	1,595,637	1,458,743
Less: accumulated depreciation	(505,917)	(318,995)
Total	$ 1,089,720	$ 1,139,748

Available-for-Sale Securities32

Available-for-Sale Securities (Details Narrative) - Blue Line Protection Group, Inc [Member]	1 Months Ended
	Mar. 31, 2015USD ($)shares
Number of common stock shares acquire during the period | shares	400,000
Number of common stock share value acquired during the period | $	$ 50,000

Available-for-Sale Securities -

Available-for-Sale Securities - Schedule of Available-for-Sale Securities (Details) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Common stock	$ 6,640	$ 9,200
Total available-for-sale securities	6,640	9,200
Amortized Cost [Member]
Common stock	50,000	50,000
Total available-for-sale securities	50,000	50,000
Gains In Accumulated Other Comprehensive Loss [Member]
Common stock
Total available-for-sale securities
Losses In Accumulated Other Comprehensive Loss [Member]
Common stock	(43,360)	(40,800)
Total available-for-sale securities	$ (43,360)	$ (40,800)

Changes in Stockholders' Equi34

Changes in Stockholders' Equity (Details Narrative) - USD ($)	Jun. 21, 2017	Mar. 02, 2017	Feb. 23, 2017	Feb. 22, 2017	Feb. 21, 2017	Feb. 07, 2017	Jan. 02, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016
Preferred stock, shares authorized								10,000,000		10,000,000
Preferred stock, par value								$ 0.001		$ 0.001
Preferred stock, shares issued								2,147,942		3,520,442
Preferred stock, shares outstanding								2,147,942		3,520,442
Common stock par value								$ 0.001		$ 0.001
Common stock authorized								90,000,000		90,000,000
Common stock, shares issued								32,040,450		22,491,041
Common Stock, shares outstanding								32,040,450		22,491,041
Number of common stock sold					1,428,575
Number of warrant shares	333,334				714,285
Sale of stock price per share					$ 0.26
Proceeds from issuance of common stock					$ 250,000			$ 300,000	$ 460,000
Stock-based compensation expense								299,760
Consultants [Member]
Stock issued for services			100,000	40,000			500,000
Common stock issued for services			$ 29,000	$ 13,600			$ 70,000
Stock-based compensation expense							$ 17,500
Six Consultants [Member]
Stock issued for services						370,000
Common stock issued for services						$ 82,251
Dr.John Abroon [Member]
Stock issued for services		100,000
Common stock issued for services		$ 20,900
Consultant In Consideration of Services [Member]
Stock issued for services		140,000
Common stock issued for services		$ 29,260
CFO [Member]
Stock issued for services		25,000
Common stock issued for services		$ 6,623
Chief Scientist [Member]
Stock issued for services		50,000
Common stock issued for services		$ 13,245
Dr. Alfredo Axtmayer [Member]
Stock issued for services				100,000
Common stock issued for services				$ 34,000
Common Stock [Member]
Number of common stock sold					1,428,575
Stock-based compensation expense								$ 224,293
Series A Convertible Preferred Stock [Member]
Preferred stock, shares designated								6,000,000
Series A Preferred Stock [Member]
Preferred stock, shares issued								2,147,942
Preferred stock, shares outstanding								2,147,942
Preferred stock convertible into common stock at fixed conversion price per share								$ 0.20
Preferred stock convertible into common stock shares								10,739,710
Percentage of equity beneficial ownership								4.99%
Stock conversion, shares converted								1,372,500
Stock conversion, shares issued								6,862,500
Common Stock [Member]
Number of common stock sold	333,334
Number of warrant shares	166,667
Sale of stock price per share	$ 0.26
Proceeds from issuance of common stock	$ 50,000

Common Stock Options (Details N

Common Stock Options (Details Narrative) - $ / shares	Jan. 02, 2017	Jun. 21, 2012	Jun. 30, 2017
Number of options outstanding			9,290,000
Number of options granted	1,530
Number of options exercised
Stock option exercise price per share	$ 3.30
2012 Stock Incentive Plan [Member]
Number of shares issued under stock plan		11,500,000

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - USD ($)	Jun. 21, 2017	Feb. 21, 2017	Jun. 30, 2017
Number of warrants outstanding	166,667
Warrant price per share	$ 0.26
Number of warrant for sale	333,334	714,285
Proceeds from issuance of warrant	$ 50,000
Warrant term	36 months
Warrant [Member]
Number of warrants outstanding		714,285	5,074,088
Warrant price per share		$ 0.26
Number of warrant for sale		1,428,575
Proceeds from issuance of warrant		$ 250,000
Number of warrants
Number of warrants exercised
Number of warrants expired
Warrant term		36 months

Other Income (Details Narrative

Other Income (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Monthly fee	$ 250,000
Former Employee [Member]
Other income	10,000	$ 16,000
GB Sciences [Member]
Rental income	3,000	$ 30,000
GB Sciences [Member] | License Agreement [Member]
Payment for settlement	$ 300,000

Income Tax (Details Narrative)

Income Tax (Details Narrative)	9 Months Ended
	Jun. 30, 2017USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 7,041,000
Operating loss expiration year	2,031

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Aug. 10, 2017	Aug. 05, 2017	Jul. 28, 2017	Jun. 21, 2017	Feb. 21, 2017
Number of common stock sold units					1,428,575
Warrant price per share				$ 0.26
Number of warrant for sale				333,334	714,285
Proceeds from issuance of warrant				$ 50,000
Subsequent Event [Member]
Number of common stock sold units		1,000,000	333,334
Stock issued during period, shares		1,000,000	333,334
Warrant price per share		$ 0.26	$ 0.26
Number of warrant for sale		500,000	166,667
Proceeds from issuance of warrant		$ 150,000	$ 50,000
Subsequent Event [Member] | Series A Preferred Stock [Member]
Stock conversion, shares converted	150,000
Stock conversion, shares issued	750,000